Exelixis, Inc. 10-Q Summary: Quarter Ended September 30, 2005
Business Context and Reporting Period
This report covers the quarterly period ended September 30, 2005. Exelixis, Inc. is a biotechnology company focused on discovering and developing pharmaceutical products for cancer, metabolic disorders, and cardiovascular disease. The company operates primarily through internal research and development and strategic collaborations with major pharmaceutical partners. As of the reporting date, the company had an accumulated deficit of $579.3 million and continues to rely on external funding and collaboration revenues to support its operations.
Key Financial Metrics
| Metric | Three Months Ended Sep 30, 2005 | Nine Months Ended Sep 30, 2005 |
|---|---|---|
| Total Revenues | $14.4 million | $61.6 million |
| Net Loss | $(22.8) million | $(59.9) million |
| Net Loss Per Share (Basic & Diluted) | $(0.29) | $(0.77) |
| Operating Expenses | $42.3 million | $126.1 million |
| Cash and Cash Equivalents | $90.0 million (as of Sep 30, 2005) | |
| Short-Term Investments | ||
| Total Liquidity (Cash + ST Investments) | $162.9 million | |
| Working Capital | $125.6 million | |
| Convertible Promissory Note (Current) | $30.0 million | |
| Convertible Promissory Loans (Long-Term) | $85.0 million |
Material Changes vs. Prior Period
- Revenue Growth: Total revenues increased 14% for the quarter and 66% for the nine-month period compared to the prior year. This was driven by milestone payments and research funding from GlaxoSmithKline, upfront payments from Helsinn Healthcare and Genentech, and the termination of the Genoptera collaboration which accelerated revenue recognition.
- Expense Trends: Research and development (R&D) expenses increased slightly (3% for the quarter, 2% for nine months) due to expanded clinical trial activities and personnel costs, partially offset by a decrease in lab supplies following the termination of combinatorial chemistry collaborations.
- Net Loss Improvement: The net loss for the nine months ended September 30, 2005, decreased significantly compared to the prior year ($59.9 million vs. $85.3 million), primarily due to the revenue acceleration from the Genoptera termination and increased collaboration income.
- Collaboration Activity: Significant new agreements were signed with Genentech (May 2005) and Helsinn Healthcare (June 2005), while the Genoptera collaboration was terminated early in March 2005, resulting in a $10.9 million termination fee.
Guidance, Outlook, and Risks
Outlook and Liquidity: Management anticipates that current cash, short-term investments, and expected funding from collaborators will sustain operations for at least the next 12 months. This estimate includes the potential repayment of a $30.0 million convertible promissory note to Protein Design Labs, Inc., due in May 2006. The company expects to incur substantial losses for the foreseeable future as it advances its clinical pipeline.
Key Developments:
- Symphony Evolution, Inc. (SEI): In June 2005, Exelixis entered into a financing arrangement with SEI to fund the clinical development of three programs (XL784, XL647, XL999). SEI is consolidated as a variable interest entity. Exelixis retains an option to reacquire these programs.
- Pipeline Progress: Eight compounds are in active clinical trials, including XL119 (Phase 3), XL784 (Phase 1), and six others in Phase 1. The company plans to file Investigational New Drug (IND) applications for additional candidates in 2006.
Risks and Contingencies:
- Capital Requirements: The company must raise additional capital to meet financial covenants with GlaxoSmithKline (working capital >$25M; cash/investments >$50M) and to repay the $30M note in 2006 if not converted.
- Dependency on Partners: Success depends heavily on collaborators (GlaxoSmithKline, Helsinn, Genentech) achieving milestones and advancing products. Helsinn controls the Phase 3 trial for XL119.
- Regulatory and Clinical Risk: Clinical trials are uncertain; failure to demonstrate safety or efficacy could delay or prevent regulatory approval.
- Accounting Changes: The company is evaluating the adoption of SFAS 123R (Share-Based Payment), effective Q1 2006, which is expected to have a material impact on reported net loss.
Investor Verification Checklist
- Verify the status and timeline for the repayment or conversion of the $30.0 million Protein Design Labs convertible note due in May 2006.
- Confirm compliance with GlaxoSmithKline financial covenants (working capital and cash/investment thresholds) to avoid default.
- Monitor the progress of the XL119 Phase 3 trial managed by Helsinn Healthcare and the delivery of clinical trial materials by April 2006.
- Assess the financial impact of the Symphony Evolution, Inc. (SEI) financing structure and the terms for reacquiring the licensed programs (XL784, XL647, XL999).
- Review the projected impact of SFAS 123R adoption on future stock-based compensation expenses and net loss.
- Track the initiation of Phase 2 trials for XL647 and XL999 and the filing of INDs for preclinical candidates (XL281, XL418, XL228) in 2006.